chrisvoncsefalvay/vaers-outcomes huggingface dataset:
7/12/2021 -- Cannot move muscle from left side: eyelid cannot close, cannot smile, difficulty speaking, and severe pain behind ear on the left side.  Visited family physician and received MRI to exclude stroke as probable cause. Doctor gave initial diagnose as Bell's Palsy 7/13/2021--visited a specialist (Otolaryngology) to confirm Bell's Palsy diagnose 7/13/2021--received steroid treatement 7/21/2021--ENoG showed 20% damage to nerve 7/28/2021 -- recovered to 40% based
10/17 8am received vaccine; 10/18 430am awoken from sleep with excruciating pain in right rib area, cramping in nature, lasting approx 15 mins 430am-9pm sore but pain free 9pm same pain in same area, doubled over in pain, collapsed due to pain, emergency dept visit, received IV fluid and Toradol; 10/19 2am goes home 4pm same pain in same area 6pm same pain in same area 10/20 no pain, just sore.
Extremely sore arm, for 2 days.  Rash under breasts to trunk appeared 2 days later.
Information was received from an attorney regarding a case in litigation concerning a male patient of unknown age. Medical history, concurrent conditions and concomitant medications were not provided. In or about 20-JAN-2015, the patient was inoculated at clinic with ZOSTAVAX (lot number, dosage, and route of administration not provided), as recommended for routine adult health maintenance and for the prevention of shingles. The ZOSTAVAX vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 06-NOV-2015, the patient was treated by a Nurse Practitioner for the onset of a severe vesicular rash accompanied by weakened immune symptoms, which was diagnosed as trigeminal shingles, a condition of nerve pain and damage affecting the trigeminal nerve of the face, neck, and ear secondary to a herpes zoster infection. The patient has been prescribed valacyclovir (VALTREX)  for management of his perisitent and painful symptoms. As a direct and proximate result of these malfunctions, he has suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, he has suffered and will continue to suffer significant medical expenses. and pain and suffering, and other damages. Additional information has been requested.
rash on back of neck or upper back region; This spontaneous case was reported by a pharmacist and describes the occurrence of RASH (rash on back of neck or upper back region) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (rash on back of neck or upper back region). At the time of the report, RASH (rash on back of neck or upper back region) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. Pharmacist stated the symptom exacerbated after patient received Moderna booster dose. No concomitant medications information was reported. No treatment medications were provided.
Woke up in the middle of the night with sharp pain on left middle side of body (kidneys?). Tried to find sleeping position that didn?t hurt but was constant pain, deep breathes were also painful. Pain went away later in morning but was sore. Was gone midday .
Vaccine administered after temperature excursion; This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after temperature excursion) in a 23-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported No treatment medications were reported
Immediately following my throat tightened and I got dizzy and very itchy, abdominal pain, loose stools, and when I stood up I felt a very sharp pain down my right arm. Diagnosed with complex regional pain syndrome, fibromyalgia.
Started with a small rash on the back and then spread all over the body. It took 1 month of antihistamines to counteract it.
patient given the child pfizer .2 ml  vaccine but the dose bottle was not diluted first with 1.3 ml of normal saline
I had chest pressure and chest pain. 160/100 - blood pressure when I checked it. I just didn't feel good. I went to my doctor - they increased my blood pressure med dosage. Next day, I saw a cardiologist  (16th) and he had another medication: Hydroclorothyrozide - HCTZ - 12.5 mg daily. Eventually they had to increase the HCTZ  about two weeks ago  and now my blood pressure is normal.
Passed out; Dehydrated; kept vomiting; Chills; her arm was swollen, itching and caused pain; arm was swollen; caused pain; A spontaneous report was received from a consumer,  concerning a 69-years-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced arm was swollen (peripheral swelling), itching (pruritus), and caused pain (pain in extremity), passed out (loss of consciousness), kept vomiting (vomiting), chills and was dehydrated (dehydration).  The patient's medical history was not provided.  Concomitant medications reported included ascorbic acid/biotin/dl-alpha tocopheryl acetate, nadolol, acetylsalicylic acid, sertraline, levothyroxine sodium and spironolactone.   On 13 Feb 2021, prior to the onset of the symptoms, the patient received their first of two planned doses of mRNA-1273 (Batch number: 030M20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection.    On 13 Feb 2021, the patient's arm was swollen, itching and caused pain for about 2 days. On 14 Feb 2021, the passed out. The patient stated that she did not know how long she was out and that the event did not happen again. Since 14 Feb 2021, the patient kept vomiting where she couldn't eat or drink at all and she could eat on 20 Feb 2021. On 14 Feb 2021, the patient had the chills and was dehydrated which lasted for 7 days. The patients' doctor told her not to get the second Moderna COVID-19 vaccination.  Treatment information was not provided.    The patient was advised by her doctor to avoid getting the second dose of mRNA-1273.  The outcome of the events, arm was swollen, itching and caused pain, were considered resolved on 15 Feb 2021. The event, passed out, was considered resolved on 14 Feb 2021. The outcome of the  events, kept vomiting and could not eat or drink at all, were considered resolved on 20 Feb 2021. The events, chills and was dehydrated, were considered resolved on 21 Feb 2021.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Rash at injection site and low grade fever. Started on zyrtec and told to FU with any s/sx of cellulitis.
Woke up this morning at 2:30 am with severe fatigue, muscle/joint aches, sore throat, feverish 99.6f, headache, nausea, and chills. Have not gone to hospital yet.
Cramps; Severe lower stomach pain; Bloated; Didn't feel good; Pressure in lower abdomen; Injection site hurt to touch with pressure; Rash on chest; Headache; Nausea; Exhaustion; This spontaneous case was reported by a consumer and describes the occurrence of MUSCLE SPASMS (Cramps), ABDOMINAL PAIN LOWER (Severe lower stomach pain), ABDOMINAL DISTENSION (Bloated), FEELING ABNORMAL (Didn't feel good) and ABDOMINAL DISCOMFORT (Pressure in lower abdomen) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MUSCLE SPASMS (Cramps), ABDOMINAL PAIN LOWER (Severe lower stomach pain), ABDOMINAL DISTENSION (Bloated), FEELING ABNORMAL (Didn't feel good), ABDOMINAL DISCOMFORT (Pressure in lower abdomen), VACCINATION SITE PAIN (Injection site hurt to touch with pressure), RASH (Rash on chest), HEADACHE (Headache), NAUSEA (Nausea) and FATIGUE (Exhaustion). At the time of the report, MUSCLE SPASMS (Cramps), ABDOMINAL PAIN LOWER (Severe lower stomach pain), ABDOMINAL DISTENSION (Bloated), FEELING ABNORMAL (Didn't feel good), ABDOMINAL DISCOMFORT (Pressure in lower abdomen), VACCINATION SITE PAIN (Injection site hurt to touch with pressure), RASH (Rash on chest), HEADACHE (Headache), NAUSEA (Nausea) and FATIGUE (Exhaustion) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported by reporter.  No treatment medications provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 13-Jul-2021: Follow-up information received contains updated information on events outcome
possible "covid arm": 3 inch diameter red spot (rash?) at injection site; mild arm pain down to elbow Rash did not appear until almost week 2 after injection.
COUGH ABDOMINAL PAIN J18.9 - Pneumonia, unspecified organism
After vaccines given, patient and mom standing at checkout desk, patient experienced LOC, fell back, landing on back, hit head on carpeted floor, no emesis, +? seizure activity lasting <5 seconds, LOC lasted <30 seconds, patient awoke on own, helped to upright position, sitting, still pale quiet, BP began to drop 82/60, patient allowed to rest supine on exam table, given water, apple juice, few bites chocolate pudding, color improved, more alert, home with mom and dad, instructions to call immediately if any concerns. Discussed sz/sx to watch/call for. Repeat BP 102/62, HR 70, cr immediate, neg Brudzinski's, EOMI; PERL, neuro exam intact, DTR's + 2/4. No swelling, abrasions, lacerations scalp; right elbow with superficial abrasion, no bleeding.
the rash was under the arm and not near the injection site; MENQUADFI possibly being administered subcutaneously instead of intramuscularly; Initial information on 21-Jul-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 16 years old female patient who experienced the rash was under the arm and not near the injection site and menquadfi possibly being administered subcutaneously instead of intramuscularly while receiving vaccine MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 18-Jul-2022, the patient received a  0.5ml dose of suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE once (strength, formulation, lot number: not reported) via subcutaneous route in the left deltoid for immunization.  On 18-JUL-2022 (latency: same day) the patient developed a non-serious the rash was under the arm and not near the injection site (rash) and menquadfi possibly being administered subcutaneously instead of intramuscularly (incorrect route of product administration) following the administration of MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE..  It was reported the rash was under the arm and not near the injection site. The reporter  states that the person who administered the vaccine stated it was given intramuscularly but the patient stated it was given subcutaneously.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events (rash ).  At time of reporting, the outcome was Unknown for the event the rash and incorrect route of product administration.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Nausea, vomiting, hands and feet cramped and stiff, stomach tightness and pain, dehydrated, ended up in ER
feeling unwell; hard breathing; This is a spontaneous report from a contactable consumer (patient).   A 58-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot Number: EW0161, expiry date: unknown) via an unspecified route of administration, administered in left arm on 21Apr2021 (at the age of 58-year-old) as dose 1, single for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, over two weeks of vaccine, the patient was feeling unwell. It was kind of hard breathing. The patient received Tylenol treatment for the event. The patient stated that he would receive the second vaccine on 12May2021. Outcome of the events was unknown at the time of reporting.  No follow-up attempts are needed. No further information is expected.
The patient has a history of allergy radiographic contrast media. Two days prior to the third vax, the patient went to the emergency room and was diagnosed with pneumonia and was given a prescription for keflex. The patient has a medical history of hypertension, and at the time of the event was taking and anti hypertensive and omeprazole. On September 14, 1999 the patient received his first injection of Engerix B for prophylaxis. Ten  hours later the patient experienced arm swelling, which resolved on October 15th 1999. On March 1, 2000 the patient received the third vax and 2 days later experienced a sore swollen arm from the elbow to the base of his neck. Also, he has mild erythema at the injection site. The patient was advised to treat the swelling with warm compresses and acetaminophen or Ibuprofen.
Patient was vaccinated in (R) with Heberix and Proquad at 12:20pm on 12/3/2019. Proquad was administered First, Followed by Heberix immediately after, (R) Deltoid started to turn red and swell, leaving a white blister.
Patient had vaccine while sitting in a chair. He stood up and seemed okay as he watched his dad get vaccine. But then he passed out and fell down.
Information has been received from a physician concerning a female patient who were vaccinated with completed series of GARDASIL. It was reported that within 2 years after completing the vaccine series the patient came back and had cervical dysplasia. Papanicolaou smears were performed. The patient sought medical attention by going to the physician's office. At the time of report the outcome was unknown. This is one of several reports from the same source. Additional information has been requested.
Client presented to clinic w/congestion and was diagnosed w/URI. Treated w/Motrin, Aurlgan Otic drops and Kenalog 0.1% ointment. Flumist administered at outreach flu clinic on 10/14 and it is not indicated for this age group.
On 12/22/01, the pt developed zoster in her right trigeminal distribution 4 months after Varivax was given. No known exposure to natural varicella/zoster. The rash progressed over 4-5 days and then start acyclovir po. No corneal involvement.
Patient reports pain and swelling at injection site. He also reports a "burning" rash on right upper arm.
pt recv vax & devel Bell's palsy w/in 24hr of vax. From follow-up #1 (12-Nov-1996), the patient was reported as not recovered as of yet. From follow-up #2 (11-Dec-1996), no recovery status was reported. From follow-up phone conservation on July 21, 1999, with doctor's office the correct updated mailing address was provided.
Pt received vaccine 12/7/12. Developed redness swelling of left thigh so severe she couldn't walk for a day was seen at our office 12/10/12. Still red & swollen. Entire left anterior thigh, walking ok treated w/ibuprofen, hydrocortisone cream.
Lethargy on first day of vaccine.   Redness around injection site starting roughly one week after injection.
Left upper extremity rash the day after injection with polyarthralgias that relieved with Tylenol at home the day after the injection. Fatigue and left upper extremity myalgia since vaccination. 1-2 cm indurated pustule noted on lateral aspect of left upper extremity, unknown if related to vaccination. No fever, chills, anaphylaxis, hives noted. All symptoms had resolved with the exception of left upper extremity muscle pain at time of office visit on 8/23/18.
pt recv vax 01OCT95&9JAN96 pt broke out in full blown chicken pox,which started on upper trunk;mom reported that the chicken pox resolved p/1wk;
swelling / at the injection site; pain at the injection site; itch all over her body / middle of her back. torso, both legs / arms / underarms; red dots and they itch; cannot sleep well at night; states both her breast hurts; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included PNEUMOCOCCAL VACCINE (PNEUMONIA VACCINE) for prophylaxis.   The patient's past medical history included psoriasis.   On 23rd September 2020, the patient received the 1st dose of Shingrix and PNEUMONIA VACCINE. On an unknown date, less than 3 months after receiving Shingrix, the patient experienced injection site swelling, injection site pain, pruritus, red spotty rash, difficulty sleeping and breast pain. The patient was treated with hydrocortisone. On an unknown date, the outcome of the injection site swelling and injection site pain were recovered/resolved and the outcome of the pruritus, red spotty rash, difficulty sleeping and breast pain were unknown.   It was unknown if the reporter considered the injection site swelling, injection site pain, pruritus, red spotty rash, difficulty sleeping and breast pain to be related to Shingrix.  Additional details were reported as follows: The patient reported that she received 1st dose of Shingrix vaccine on left arm and on same day received Pneumonia vaccine on right arm. The patient experienced there was a swelling and pain at the injection site on the left arm which was resolved, but later, started to itch all over her body, the middle of back, torso, both legs and arms and also underarm. Sometimes they appeared as a red dots and they itch, but red dost went away. The patient stated most of her itching was at the torso. The patient stated because of the itching, she could not sleep well at night. The patient reported that both her breast hurts. The patient was seen by dermatologist who started some hydrocortisone cream. The reporter consented to follow up.
No additional adverse event.; the patient was inadvertently administered a dose of ROTATEQ on 3/3/2020 that had been improperly stored.; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. No information about the patient's pertinent medical history, concurrent conditions, concomitant medications and drug reactions or allergies was provided.  On 03-MAR-2020, the patient was inadvertently administered an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) orally, lot # S006050 with expiration date of 12-DEC-2020, for prophylaxis.        No adverse effects were reported.  It was stated that the vaccines underwent a temperature excursion in  08-FEB-2020, of above 47F (degrees Fahrenheit) (50.9F) for 30 minutes; on 25-FEB-2020, of above 47F (52.7F) for 15 minutes; on 03-MAR-2020, of above 47F (50.7F) for 25 minutes.  No previous temperature excursion was done. The call was because of a "data logger".
Shortly after receiving flu shot, sensation of being physically unbalanced, slightly dizzy and impaired cogitatively (ie: feeling of sudden tiredness and difficulty thinking). These symptoms persisted throughout the afternoon but seemed to be diminishing. Approx. 4 hours later, raised hives developed in a ring around neck and a wheezing, dry, reflux cough developed. Shortly after this I was having a difficult time breathing and had tightness in throat. I went to local Urgent Care. During my time at Urgent Care both eyes became swollen and itchy, bloodshot along with nausea.
Mild-moderate left arm pain; This is a spontaneous report from a contactable consumer, the parent. A 16-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 01Mar2021 at 15:15 (at the age of 16-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have any allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 23Mar2021 at 22:00, the patient experienced mild to moderate left arm pain. The patient did not receive any treatment for the event. The clinical outcome of event left arm pain was resolving at the time of this report. Information about lot/batch number has been requested.
nausea x5 days-vomiting x1 on 4th day of nausea sx-no other symptoms;
Pneumococcal vaccination given 6/14/07; that evening developed pink, swelling, near and below injection site in left deltoid. She took Tylenol at 0300 and applied cold beverage bottle to area; returns today and involved area is about "1: below injection site, medially down to "1" above antecubital region, states area is tender. Patient is afebrile contacted MD - patient seen by MD, Keflex prescribed- later that evening patient presented to ED for overnight stay.
Post vax, pt developed croup and high fever. Within two weeks, he had developed speech loss from approximately 50 words to 2 or 3 words.
She was hospitalized for a month Occurred after a flu two months prior and a stomach flu 2-3 weeks prior; She was hospitalized for a month Occurred after a flu two months prior and a stomach flu 2-3 weeks prior; This is a spontaneous report from a contactable consumer. A 75-year-old female patient received bnt162b2 (BNT162B2, lot number and expiry date were not reported), via an unspecified route of administration on an unspecified date at a single dose for covid-19 vaccination. Medical history included guillain-barre syndrome from 2011 at the age of 65 and Levaquin allergy. The patient's concomitant medications were not reported. On an unspecified date, the patient was hospitalized for a month that occurred after a flu two months prior and a stomach flu 2-3 weeks prior. The outcome of the events was unknown.  Information about lot/batch number has been requested.
ADMINISTRATION ERROR - PENTACEL POWDER MIXED WITH STERILE WATER INSTEAD OF PENTACEL DILUENT IN PACKAGE.